InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
masterofdisaster Free
09/22/21 7:36 AM
profile icon
masterofdisaster Free
09/22/21 6:48 AM
profile icon
gene_genome Free
09/21/21 7:12 PM
profile icon
masterofdisaster Free
09/21/21 5:47 PM
profile icon
Jess070283 Free
09/21/21 3:36 PM
profile icon
masterofdisaster Free
09/21/21 3:33 PM
profile icon
spindog Free
09/21/21 3:29 PM
profile icon
TheFinalCD PremiumMember
09/21/21 3:22 PM
profile icon
spindog Free
09/21/21 3:22 PM
profile icon
masterofdisaster Free
09/21/21 2:45 PM
profile icon
BooDog Free
09/21/21 2:22 PM
profile icon
masterofdisaster Free
09/21/21 2:18 PM
profile icon
masterofdisaster Free
09/21/21 2:08 PM
profile icon
BoilerRoom Free
09/21/21 1:34 PM
profile icon
BooDog Free
09/21/21 1:30 PM
profile icon
BoilerRoom Free
09/21/21 1:29 PM
profile icon
BooDog Free
09/21/21 1:27 PM
profile icon
masterofdisaster Free
09/21/21 12:58 PM
profile icon
BoilerRoom Free
09/21/21 12:27 PM
profile icon
BoilerRoom Free
09/21/21 12:25 PM
profile icon
ollik78 Free
09/21/21 12:25 PM
profile icon
BoilerRoom Free
09/21/21 11:49 AM
profile icon
BoilerRoom Free
09/21/21 11:48 AM
profile icon
masterofdisaster Free
09/21/21 10:51 AM
profile icon
BoilerRoom Free
09/21/21 10:35 AM
profile icon
BoilerRoom Free
09/21/21 10:34 AM
profile icon
BoilerRoom Free
09/21/21 10:16 AM
profile icon
jxphilli Free
09/21/21 8:16 AM
profile icon
Biggeoff Free
09/21/21 7:18 AM
profile icon
masterofdisaster Free
09/21/21 6:38 AM
profile icon
BoilerRoom Free
09/21/21 12:02 AM
profile icon
jxphilli Free
09/20/21 10:48 PM
profile icon
masterofdisaster Free
09/20/21 7:34 PM
profile icon
masterofdisaster Free
09/20/21 7:33 PM
profile icon
BoilerRoom Free
09/20/21 6:47 PM
profile icon
jxphilli Free
09/20/21 6:25 PM
profile icon
masterofdisaster Free
09/20/21 4:32 PM
profile icon
BoilerRoom Free
09/20/21 4:07 PM
profile icon
jxphilli Free
09/20/21 2:50 PM
profile icon
~MulaGreen~ Free
09/20/21 2:45 PM
profile icon
ollik78 Free
09/20/21 2:29 PM
profile icon
masterofdisaster Free
09/20/21 2:25 PM

Corvus Pharmaceuticals Inc (CRVS) RSS Feed

Followers
22
Posters
47
Posts (Today)
0
Posts (Total)
262
Created
04/04/17
Type
Free
Moderators



https://www.corvuspharma.com/

https://www.phillyvoice.com/temple-covid19-immunotherapy-clinical-trial-corvus-coronavirus-research/

https://clinicaltrials.gov/ct2/show/NCT04464395?type=Intr&cond=COVID-19&sort=nwst&draw=2
 

July 7, 2020 09:36 AM ET (BZ Newswire) -- News

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) are "" rel="nofollow ugc" target="_blank">https://www.benzinga.com/pre-market-outlook/20/07/16530313/18-healthcare-stocks-moving-in-tuesdays-pre-market-session"; rel="nofollow ugc">advancing strongly Tuesday following an announcement concerning its foray into COVID-19 treatment.

What Happened: The Burlingame, California-based company said the FDA has reviewed and accepted its investigational new drug application for initiating a COVID-19 study. Accordingly, the company said it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.

The company said it's studying an agonistic humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

CPI-006, according to the company, has demonstrated binding to various immune cells and the inducement of a humoral adaptive immune response – B cell activation and lymphocyte trafficking leading to the production of antigen-specific immunoglobulin antibodies.

It has also led to increased levels of memory B cells, which are the cells responsible for long-term immunity, it added.

The company said these may provide immediate and long-term clinical benefits, including shortened recovery time and improved long-term protective immunity, for patients infected by SARS-CoV-2, the virus that causes COVID-19.

What's Next: Corvus expects to enroll up to 30 COVID-19 patients with mild to moderate symptoms in the Phase 1 study, with the patients receiving a single dose of CPI-006, with levels of 0.3, 1, 3 and 5 mg/kg, escalating in four cohorts as the study progresses.

The primary efficacy endpoint is the change in serum immunoglobulin anti-SARS-CoV-2 levels compared to baseline at day 28.
The study also will examine the safety and other clinical endpoints, including time to resolution of symptoms and duration of hospitalization.

The company expects to report data from the study later this year.

If the study meets its objectives, Corvus said it intends to work with the FDA to initiate a broader, randomized study at a fixed dose of CPI-006 that could potentially be adapted into a pivotal study to support a regulatory submission for FDA approval.

Shares were rallying 85.04% to $5.07

 


 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post